Hong Kong: Akeso Biopharma completes HK$582m private placement

PRC-based integrated drug discovery platform, Akeso Biopharma, has raised HK$582m (US$74.1m) from a primary placement. The deal, comprising 24m shares or 2.9% of the enlarged share capital, was priced at the bottom of the indicative price range of HK$24.27–$25.06 per share. The price represents a 7% discount to the reference closing price of HK$26.10. Proceeds are…

You must be a HMI Subscriber to view this content.

Subscribe Now »